title: A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs.
abstract: Over the past decade the development of safer reduced-intensity conditioning regimens, expanded donor pools, advances in supportive care, and prevention/management of graft-versus-host disease have expanded stem cell transplantation (SCT) availability for chronic lymphocytic leukemia (CLL) patients. However, there are now increasingly active treatment options available for CLL patients with favorable toxicity profiles and convenient administration schedules. This raises the critical issue of whether or not attainment of cure remains a necessary goal. It is now less clear that treatment with curative intention and with significant toxicity is required for long-term survival in CLL. In addition, the demonstrated safety and activity of genetically modified chimeric antigen receptor (CAR) T cells present the opportunity of harnessing the power of the immune system to kill CLL cells without the need for SCT. We attempt to define the role of SCT in the era of targeted therapies and discuss questions that remain to be answered. Furthermore, we highlight the potential for exciting new cellular therapy using genetically modified anti-CD19 CAR T cells and discuss its potential to alter treatment paradigms for CLL.
authors.affiliation: Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, PA.
authors.forename: Anthony
authors.initials: A
authors.lastname: Mato
authors.affiliation: Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, PA.
authors.forename: David L
authors.initials: DL
authors.lastname: Porter
mesh_terms: D017690:Cell Transplantation; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000628:therapy*; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*; D013997:Time Factors; D014184:Transplantation, Homologous
chemical_list: D011948:Receptors, Antigen, T-Cell